Hypoactive sexual desire disorder

被引:3
|
作者
Davison, Sonia L. [1 ]
机构
[1] Monash Univ, Womens Hlth Res Program, Dept Epidemiol & Prevent Med, Sch Publ Hlth & Prevent Med,Alfred Ctr, Melbourne, Vic 3004, Australia
关键词
female sexual dysfunction; hypoactive sexual desire disorder; women; PREMENOPAUSAL WOMEN EFFICACY; PLACEBO-CONTROLLED TRIAL; POSTMENOPAUSAL WOMEN; MENOPAUSAL WOMEN; TESTOSTERONE PATCH; ANDROGEN LEVELS; SAFETY; FLIBANSERIN; THERAPY; DYSFUNCTIONS;
D O I
10.1097/GCO.0b013e328355847e
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Purpose of review Hypoactive sexual desire disorder (HSDD) is the most prevalent female sexual dysfunction, with estimates of prevalence approximating 10%. By definition it is a deficiency of sexual desire that causes distress. HSDD has no single cause, but physiological, psychological and socio-cultural factors underpinning female sexual desire may all be important in its development. Recent findings Medical therapeutic strategies to date have concentrated on modulation of hormone levels, particularly androgen administration, yet few products have been approved for the treatment of HSDD in developed countries. More recent medical targets have included agents with 5-hydroxytryptamine agonist activity. Psychological therapeutic approaches have been infrequently studied but concentrate on cognitive behavioural therapy. Summary HSDD is an evolving diagnosis, the existence of which has been questioned by some critics. Whilst HSDD remains the subject of ongoing research, its title and definition are under debate as a new edition of the Diagnostic and Statistical Manual of the American Psychiatric Association approaches publication in 2012.
引用
收藏
页码:215 / 220
页数:6
相关论文
共 50 条
  • [31] Targeting Circuits of Sexual Desire as a Treatment Strategy for Hypoactive Sexual Desire Disorder
    Stahl, Stephen M.
    JOURNAL OF CLINICAL PSYCHIATRY, 2010, 71 (07) : 821 - 822
  • [32] Efficacy and Safety of Testosterone in the Management of Hypoactive Sexual Desire Disorder in Postmenopausal Women
    Davis, Susan R.
    Braunstein, Glenn D.
    JOURNAL OF SEXUAL MEDICINE, 2012, 9 (04) : 1134 - 1148
  • [33] The DSM Diagnostic Criteria for Hypoactive Sexual Desire Disorder in Men
    Brotto, Lori A.
    JOURNAL OF SEXUAL MEDICINE, 2010, 7 (06) : 2015 - 2030
  • [34] The Treatment of Hypoactive Sexual Desire Disorder
    Weeks, Gerald
    Hertlein, Katherine
    Gambescia, Nancy
    JOURNAL OF FAMILY PSYCHOTHERAPY, 2009, 20 (2-3) : 129 - 149
  • [35] Role of flibanserin in managing hypoactive sexual desire disorder in women: A systematic review and meta-analysis
    Kamrul-Hasan, A. B. M.
    Hannan, Mohammad Abdul
    Alam, Muhammad Shah
    Aalpona, Fatema Tuz Zahura
    Nagendra, Lakshmi
    Selim, Shahjada
    Dutta, Deep
    MEDICINE, 2024, 103 (25)
  • [36] Pharmacologic treatment options for hypoactive sexual desire disorder
    Bolour, Sheila Y.
    Braunstein, Glenn D.
    WOMENS HEALTH, 2005, 1 (02) : 263 - 277
  • [37] Validation of the Sexual Interest and Desire Inventory-Female in Hypoactive Sexual Desire Disorder
    Clayton, Anita H.
    Goldmeier, David
    Nappi, Rossella E.
    Wunderlich, Glen
    Lewis-D'Agostino, Diane J.
    Pyke, Robert
    JOURNAL OF SEXUAL MEDICINE, 2010, 7 (12) : 3918 - 3928
  • [38] Instruments for Screening, Diagnosis, and Management of Patients with Generalized Acquired Hypoactive Sexual Desire Disorder
    Derogatis, Leonard R.
    Revicki, Dennis A.
    Clayton, Anita H.
    JOURNAL OF WOMENS HEALTH, 2020, 29 (06) : 806 - 814
  • [39] Open-Label Extension Study of Flibanserin in Women with Hypoactive Sexual Desire Disorder
    Jayne, Christopher
    Simon, James A.
    Taylor, Leslie V.
    Kimura, Toshio
    Lesko, Lynna M.
    JOURNAL OF SEXUAL MEDICINE, 2012, 9 (12) : 3180 - 3188
  • [40] Flibanserin: a potential treatment for Hypoactive Sexual Desire Disorder in premenopausal women
    Clayton, A. H.
    Dennerstein, L.
    Pyke, R.
    Sand, M.
    WOMENS HEALTH, 2010, 6 (05) : 639 - 653